Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.

Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL.

PLoS One. 2012;7(4):e34414. doi: 10.1371/journal.pone.0034414. Epub 2012 Apr 11.

2.

Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.

Maruyama Y, Miyazaki T, Ikeda K, Okumura T, Sato W, Horie-Inoue K, Okamoto K, Takeda S, Inoue S.

PLoS One. 2014 Oct 6;9(10):e108743. doi: 10.1371/journal.pone.0108743. eCollection 2014.

3.

Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.

Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J.

Prostate. 2015 Aug 1;75(11):1187-96. doi: 10.1002/pros.23000. Epub 2015 Apr 20.

PMID:
25894097
4.

AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.

McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ.

J Cell Biochem. 2010 Aug 1;110(5):1187-94. doi: 10.1002/jcb.22633.

6.

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.

Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.

PMID:
18324645
7.

Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.

Quéro L, Giocanti N, Hennequin C, Favaudon V.

Prostate. 2010 Mar 1;70(4):401-11. doi: 10.1002/pros.21074.

PMID:
19902473
8.

Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.

Hoang DT, Gu L, Liao Z, Shen F, Talati PG, Koptyra M, Tan SH, Ellsworth E, Gupta S, Montie H, Dagvadorj A, Savolainen S, Leiby B, Mirtti T, Merry DE, Nevalainen MT.

Mol Cancer Ther. 2015 Mar;14(3):713-26. doi: 10.1158/1535-7163.MCT-14-0819. Epub 2014 Dec 31.

9.

Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.

Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.

Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5.

PMID:
22072572
10.

Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.

Danquah M, Duke CB 3rd, Patil R, Miller DD, Mahato RI.

Pharm Res. 2012 Aug;29(8):2079-91. doi: 10.1007/s11095-012-0737-1. Epub 2012 Mar 27.

PMID:
22451249
11.

CSL regulates AKT to mediate androgen independence in prostate cancer progression.

Wang H, Zhang L, Fu Y, Fang F, Jiang Y, Dong Y, Zhu W.

Prostate. 2016 Feb;76(2):140-50. doi: 10.1002/pros.23104. Epub 2015 Oct 6.

PMID:
26437743
13.

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM.

Mol Cancer Ther. 2007 Jan;6(1):51-60. Epub 2007 Jan 11.

14.

Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?

Bennett HL, Stockley J, Fleming JT, Mandal R, O'Prey J, Ryan KM, Robson CN, Leung HY.

BJU Int. 2013 Apr;111(4):672-82. doi: 10.1111/j.1464-410X.2012.11409.x. Epub 2012 Aug 16.

15.

Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells.

Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K.

Mol Cancer Ther. 2010 Dec;9(12):3175-85. doi: 10.1158/1535-7163.MCT-10-0368.

16.

Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.

Boutin B, Tajeddine N, Vandersmissen P, Zanou N, Van Schoor M, Mondin L, Courtoy PJ, Tombal B, Gailly P.

Prostate. 2013 Jul;73(10):1090-102. doi: 10.1002/pros.22658. Epub 2013 Mar 26.

PMID:
23532738
17.

Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.

Mashima T, Okabe S, Seimiya H.

Mol Pharmacol. 2010 Nov;78(5):846-54. doi: 10.1124/mol.110.064790. Epub 2010 Aug 13.

18.

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.

Endocr Relat Cancer. 2005 Mar;12(1):119-34.

19.

ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C.

Neoplasia. 2012 Jan;14(1):74-83.

20.

Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.

Liu R, Sun J, Zhang Z, Xu Y.

Cell Biol Int. 2012 Oct 1;36(10):863-72. doi: 10.1042/CBI20110662.

PMID:
22612256

Supplemental Content

Support Center